Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
13actual
Sites
12
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-28
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-23 | actual | When the study began enrolling |
| Primary completion | 2022-02-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-28 | actual | The whole study's end, after follow-up |
| First posted | 2020-07-20 | actual | When this record first appeared on the registry |
| Results posted | 2025-01-14 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mantle Cell Lymphoma (MCL)
Interventions
- Drug: Ibrutinib — also filed as Imbruvica
- Drug: Venetoclax — also filed as ABT-199, Venclexta, GDC-0199, Venclyxto
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC)
measured Week 13
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-11-17 · 2.0 MB · Prot_000.pdf
Statistical Analysis Planposted 2022-04-16 · 413 KB · SAP_001.pdf
Related
ABBV · their whole pipeline · Who in Congress owns ABBV? · Executive-branch trades in ABBV
ABBV's other studiesmost recently updated first
- A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) Phase 1 · Active, not recruiting
- Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 2/3 · Recruiting
- A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer Phase 3 · Recruiting
- A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Phase 2/3 · Recruiting
- A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants Phase 1 · Active, not recruiting
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed